DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

GlaxoSmithKline (NYSE: GSK)

47.10 -0.20 (-0.42%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GSK $47.10 -0.42%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.26
Previous Close $47.30
Daily Range $47.02 - $47.37
52-Week Range $46.01 - $56.73
Market Cap $113.1B
P/E Ratio 16.25
Dividend (Yield) $2.59 (5.6%)
Ex-Dividend Date
Dividend Pay Date
08/06/14
10/02/14
Volume 5,022,604
Average Daily Volume 3,577,352
Current FY EPS $3.19

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014

Sarepta Therapeutics stock has been whipsawed over the past year. Find out what's been the cause of its volatility and whether or not the stock can head higher.

Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog

After Hours Most Active for Sep 17, 2014 : GSK, QQQ, BAC, PSX, KORS, SQNM, FOXA, INTC, PIR, RFMD, P

After Hours Most Active for Sep 17, 2014 : GSK, QQQ, BAC, PSX, KORS, SQNM, FOXA, INTC, PIR, RFMD, PLCM, MHK

Could GlaxoSmithKline Be A Better Investment Than Gilead?

Cramer's Mad Money - The World Is Slowing, And Slowing Fast (9/16/14)

Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF

Is It Time to Buy GlaxoSmithKline plc Stock?

GlaxoSmithKline's stock has had a rough year due to falling revenues. Can the stock rebound?

Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog

Terrific Stocks On Sale: Part 1

COPD Occurs Most Often in These 5 States

COPD affects more than 6% of the U.S. population and costs $50 billion in direct and indirect costs annually, but these five states have the highest occurrence rate in the country.

See More GSK News...

GSK's Top Competitors

GSK $47.10 (-0.42%)
Current stock: GSK
JNJ $106.19 (0.29%)
Current stock: JNJ
NVS $94.72 (0.36%)
Current stock: NVS
RHHBY $37.37 (-0.31%)
Current stock: RHHBY